BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clini

– Results from successful drug-impregnation of PGX liquid processed alginate hydrogel scaffolds further bolsters Ceapro’s efforts to develop innovative delivery systems composed of new chemical complexes – – Study indicates that PGX-alginate can provide a unique set of properties useful for accelerating the wound healing process – EDMONTON, Alberta, June 15, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnolo

Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy,” was published in the peer-reviewed journal Investigative Ophthalmology & Visual Scie

- Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels - 3 (60%) of the 5 patients remain on treatment with durable response demonstrated: 6, 12 and 15 months, respectively, following the initial response; 1 patient went on to transplant - Phase 2: Of the 7 patients having completed 1 cycle of treatment, 2 (28%) achieved an objective response; 1 had

BioIQ , a healthcare engagement and clinical adherence technology platform company, announced today availability of the first home test for COVID-19 that combines COVID-19, Flu A / Flu B, and a 21 Test Respiratory Pa

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets. The new three-year research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as par

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters , Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, has published a white paper detailing his

MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency’s Micro, Small and Medium-Sized Enterprise office.

Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company, and Pharmco, Greenfield Global’s popular brand of specialty al